These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 39265563)

  • 41. Prognostic value of computed tomography‑derived skeletal muscle index and radiodensity in patients with gastric cancer after curative gastrectomy.
    Hashimoto I; Komori K; Maezawa Y; Nagasawa S; Kawabe T; Aoyama T; Hayashi T; Yamada T; Sato T; Ogata T; Cho H; Yoshikawa T; Yukawa N; Rino Y; Saito A; Oshima T
    Oncol Lett; 2024 Oct; 28(4):458. PubMed ID: 39114573
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Relationship Between Pretreatment Body Composition and Clinical Outcomes in Patients With Metastatic Renal Cell Carcinoma Receiving First-Line Ipilimumab Plus Nivolumab.
    McManus HD; Zhang D; Schwartz FR; Wu Y; Infield J; Ho E; Armstrong AJ; George DJ; Kruse D; Gupta RT; Harrison MR
    Clin Genitourin Cancer; 2023 Dec; 21(6):e429-e437.e2. PubMed ID: 37271698
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Lymphocyte-to-Monocyte Ratio Is a Predictive Biomarker of Response to Treatment with Nivolumab for Gastric Cancer.
    Tokumaru S; Koizumi T; Sekino Y; Takeuchi N; Nakata S; Miyagawa Y; Kitazawa M; Muranaka F; Nakamura S; Koyama M; Yamamoto Y; Ehara T; Hondo N; Soejima Y
    Oncology; 2021; 99(10):632-640. PubMed ID: 34280933
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Correlation between L3 skeletal muscle index and prognosis of patients with stage IV gastric cancer.
    Kang Z; Cheng L; Li K; Shuai Y; Xue K; Zhong Y; Chen L
    J Gastrointest Oncol; 2021 Oct; 12(5):2073-2081. PubMed ID: 34790375
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Overall survival and PD-L1 expression in patients with recurrent or metastatic head and neck cancer treated with nivolumab.
    Okamoto I; Sato H; Tsukahara K
    Auris Nasus Larynx; 2020 Aug; 47(4):676-686. PubMed ID: 32439271
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Systemic inflammatory response and nutritional biomarkers as predictors of nivolumab efficacy for gastric cancer.
    Namikawa T; Yokota K; Tanioka N; Fukudome I; Iwabu J; Munekage M; Uemura S; Maeda H; Kitagawa H; Kobayashi M; Hanazaki K
    Surg Today; 2020 Nov; 50(11):1486-1495. PubMed ID: 32542414
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prognostic Impact of Sarcopenia and Skeletal Muscle Loss During Neoadjuvant Chemoradiotherapy in Esophageal Cancer.
    Yoon HG; Oh D; Ahn YC; Noh JM; Pyo H; Cho WK; Song YM; Park M; Hwang NY; Sun JM; Kim HK; Zo JI; Shim YM
    Cancers (Basel); 2020 Apr; 12(4):. PubMed ID: 32290037
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The prognostic value of prognostic nutritional index in advanced cancer receiving PD-1/L1 inhibitors: A meta-analysis.
    Li P; Lai Y; Tian L; Zhou Q
    Cancer Med; 2022 Aug; 11(16):3048-3056. PubMed ID: 35297197
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Impact of Skeletal Muscle Mass Reduction on Long-term Survival After Radical Resection of Gastric Cancer.
    Tanaka Y; Aoyagi K; Umetani Y; Tanaka YU; Kaku H; Minami T; Isobe T; Murakami N; Fujita F; Akagi Y
    Anticancer Res; 2023 Aug; 43(8):3779-3786. PubMed ID: 37500123
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Body mass index and skeletal muscle index are useful prognostic factors for overall survival after gastrectomy for gastric cancer: Retrospective cohort study.
    Kim EY; Jun KH; Kim SY; Chin HM
    Medicine (Baltimore); 2020 Nov; 99(47):e23363. PubMed ID: 33217879
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Creatinine-to-cystatin C ratio and body composition predict response to PD-1 inhibitors-based combination treatment in metastatic gastric cancer.
    Ji H; Liu B; Jin P; Li Y; Cui L; Jin S; Wu J; Shan Y; Zhang Z; Ming J; Zhang L; Du C
    Front Immunol; 2024; 15():1364728. PubMed ID: 38665913
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab.
    Liu J; Li S; Zhang S; Liu Y; Ma L; Zhu J; Xin Y; Wang Y; Yang C; Cheng Y
    J Clin Lab Anal; 2019 Oct; 33(8):e22964. PubMed ID: 31282096
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The prognostic value of prognostic nutritional index (PNI) and neutrophil to lymphocyte ratio (NLR) for advanced non-small cell lung cancer treated with platinum-based chemotherapeutics.
    Wang J; Liu Y; Mi X; Shao M; Liu L
    Ann Palliat Med; 2020 May; 9(3):967-978. PubMed ID: 32389020
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prognostic Impact of the Loss of Skeletal Muscle Mass During Neoadjuvant Chemotherapy on Older Patients with Esophageal Cancer.
    Harada T; Tsuji T; Ueno J; Koishihara Y; Konishi N; Hijikata N; Ishikawa A; Kotani D; Kojima T; Fujiwara H; Fujita T
    Ann Surg Oncol; 2022 Dec; 29(13):8131-8139. PubMed ID: 35978207
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pretreatment prognostic nutritional index as a novel biomarker in non-small cell lung cancer patients treated with immune checkpoint inhibitors.
    Shoji F; Takeoka H; Kozuma Y; Toyokawa G; Yamazaki K; Ichiki M; Takeo S
    Lung Cancer; 2019 Oct; 136():45-51. PubMed ID: 31437663
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Preoperative nutritional risk index and postoperative one-year skeletal muscle loss can predict the prognosis of patients with gastric adenocarcinoma: a registry-based study.
    Kim KW; Lee K; Lee JB; Park T; Khang S; Jeong H; Ko CS; Yook JH; Kim BS; Lee IS
    BMC Cancer; 2021 Feb; 21(1):157. PubMed ID: 33579228
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prognostic significance of body mass index and prognostic nutritional index in stage II/III gastric cancer.
    Park SH; Lee S; Song JH; Choi S; Cho M; Kwon IG; Son T; Kim HI; Cheong JH; Hyung WJ; Choi SH; Noh SH; Choi YY
    Eur J Surg Oncol; 2020 Apr; 46(4 Pt A):620-625. PubMed ID: 31668977
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Skeletal Muscle Mass Influences Tolerability and Prognosis in Hepatocellular Carcinoma Patients Treated with Lenvatinib.
    Uojima H; Chuma M; Tanaka Y; Hidaka H; Nakazawa T; Iwabuchi S; Kobayashi S; Hattori N; Ogushi K; Morimoto M; Kagawa T; Tanaka K; Kako M; Koizumi W
    Liver Cancer; 2020 Apr; 9(2):193-206. PubMed ID: 32399433
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pretreatment body mass index predicts survival among patients administered nivolumab monotherapy for pretreated non-small cell lung cancer.
    Imai H; Naito E; Yamaguchi O; Hashimoto K; Iemura H; Miura Y; Shiono A; Mouri A; Kaira K; Kobayashi K; Kagamu H
    Thorac Cancer; 2022 May; 13(10):1479-1489. PubMed ID: 35394119
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Low skeletal muscle mass predicts poor prognosis for patients with stage III cervical cancer on concurrent chemoradiotherapy.
    Aichi M; Hasegawa S; Kurita Y; Shinoda S; Kato S; Mizushima T; Yokota NR; Miyagi E
    Nutrition; 2023 May; 109():111966. PubMed ID: 36731243
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.